FINWIRES · TerminalLIVE
FINWIRES

Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease

By

Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.

The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.

Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.

SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.

Shares of Serina Therapeutics rose more than 9% in Thursday trading.

Price: $2.19, Change: $+0.19, Percent Change: +9.50%

Related Articles

Wire

Republic Power Group Regains Nasdaq Minimum Bid Price Compliance

Republic Power Group (RPGL) regained compliance with the Nasdaq Stock Market minimum bid price requirement.Nasdaq has closed the matter, the company said Wednesday in a statement.Republic Power shares jumped 34% in after-hours trading.

$RPGL
Wire

Byrna Technologies to Acquire HERO Defense Systems for $1.25 Million in Cash, Stock

Byrna Technologies (BYRN) agreed to acquire HERO Defense Systems $1.25 million in cash and stock, adding compact everyday-carry personal defense products to its lineup.The consideration includes $625,000 in cash, $625,000 in restricted shares, and a performance-based royalty tied to future net sales of HERO products, Byrna said Wednesday in a statement.The transaction is expected to close within 30 days.Byrna shares rose 4.9% in after-hours trading.

$BYRN
Wire

Ampco-Pittsburgh Reports Higher Customer Order Activity for H1

Ampco-Pittsburgh (AP) said Wednesday its customer order activity in the first half of 2026 totaled about $268 million, up from $204 million in the same period a year earlier.Customer order activity in the company's Forged and Cast Engineered Products segment rose 25% in the first six months of 2026, while Air and Liquid Processing experienced 42% growth year over year, according to a statement.Shares rose more than 15% in after-hours trading.

$AP